SEC Declares Form S-4 Registration Statement “Effective” for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.

Larkspur has scheduled a particular assembly of their stockholders to hunt approval and adoption of the Enterprise Mixture Settlement and the transactions contemplated thereby (the “Transaction”), and different associated issues, a key milestone within the enterprise mixture course of.

The Larkspur particular assembly of stockholders might be held on December 8, 2022, at 10:00 am Jap Time at https://www.cstproxy.com/lsprhealth/2022. Larkspur’s frequent stockholders of document as of the shut of enterprise on November 8, 2022, are entitled to obtain discover of, to vote, and have their votes counted on the particular assembly and any adjournment thereof. Larkspur’s stockholders might be mailed the proxy assertion and prospectus in reference to the Transaction starting November 14, 2022. The Registration Assertion containing the proxy assertion and prospectus incorporates necessary details about the proposed Transaction, the Enterprise Mixture Settlement, and the proposals to be thought-about on the particular assembly. The Registration Assertion containing the proxy assertion, prospectus, and proposals to be thought-about is out there by way of the SEC’s web site at www.sec.gov or at www.lsprhealth.com.

“We’re delighted to companion with ZyVersa on this enterprise mixture,” mentioned Daniel J. O’Connor, Chairman and Chief Govt Officer of Larkspur. “We consider that ZyVersa has potential to construct stockholder worth, based mostly on its distinctive worth proposition summarized beneath,” continued Mr. O’Connor.

• Two proprietary drug platforms to deal with vital unmet wants of sufferers with renal ailments (VAR 200) and inflammatory ailments (IC 100)
• A section 2a-ready lead renal product candidate, VAR 200, which mediates elimination of extra intracellular lipids that contribute to kidney injury resulting in end-stage renal illness
• A lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), which blocks initiation and perpetuation of damaging irritation that is pathogenic in a large number of inflammatory ailments
• An skilled CEO, Mr. Stephen Glover, who has co-founded and led a number of biopharma corporations
• A Administration crew with deep scientific, industrial, and operational expertise

The closing of the Transaction, which is anticipated to happen within the fourth quarter of 2022, is topic to approval by Larkspur’s stockholders and the opposite closing circumstances set forth within the definitive Enterprise Mixture Settlement. Upon closing of the Transaction, Larkspur is anticipated to be renamed ZyVersa Therapeutics, Inc., and can proceed to function underneath the ZyVersa administration crew, led by Stephen C. Glover, Co-Founder, Chief Govt Officer, and Chairman of ZyVersa. The mixed firm’s frequent inventory is anticipated to be listed on NASDAQ underneath ticker image “ZVSA.”

About Larkspur Well being Acquisition Corp.

Larkspur is a Particular Function Acquisition Firm (SPAC) fashioned to determine a biopharmaceutical firm that may develop and thrive as a newly fashioned public firm, and profit from Larkspur’s operational experience and a major infusion of capital. Every of Larkspur’s administration crew and board of administrators have been former administration and govt management of personal and public biopharmaceutical corporations and have over 50+ years of combination funding and operational experiences. The crew strongly believes within the development alternatives within the biotechnology trade. They’re skilled operators who search to companion with prime innovators and thinkers within the biopharmaceutical area. Their entrepreneurial method helps administration groups in making impactful choices with an eye fixed towards development and operational excellence. For extra data, please go to www.lsprhealth.com.

About ZyVersa Therapeutics, Inc.

ZyVersa is a scientific stage specialty biopharmaceutical firm leveraging superior, proprietary applied sciences to develop product candidates that tackle unmet medical wants within the areas of renal and inflammatory ailments. ZyVersa’s growth pipeline consists of section 2a prepared VAR 200, a ldl cholesterol efflux mediator for remedy of uncommon kidney illness, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to deal with different glomerular ailments, together with Alport syndrome and diabetic kidney illness. ZyVersa’s growth pipeline additionally consists of IC 100, a novel inflammasome ASC inhibitor being developed to deal with a large number of inflammatory ailments. For extra data, please go to www.zyversa.com.

Necessary Data for Traders and Stockholders and The place to Discover It

In reference to the transactions described herein, Larkspur filed its Registration Assertion on Type S-4 that features a proxy assertion with respect to the stockholder assembly of Larkspur and a prospectus with respect to securities of the mixed firm. After the Registration Assertion is asserted efficient by the SEC, the proxy assertion/prospectus might be despatched to all Larkspur and ZyVersa stockholders. Larkspur may also file different paperwork relating to the proposed Enterprise Mixture with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITIES HOLDERS OF LARKSPUR AND ZYVERSA ARE URGED TO READ THE REGISTRATION STATEMENT, INCLUDING THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION. 

Traders and securities holders will have the ability to get hold of free copies of the Registration Assertion, proxy assertion/prospectus and all different related paperwork filed or that might be filed with the SEC by Larkspur by way of the web site maintained by the SEC at https://sec.gov/. As well as, the paperwork filed by Larkspur could also be obtained freed from cost from Larkspur’s web site at www.lsprhealth.com or by written request to [email protected]. Extra details about the proposed Transaction, together with a replica of the Enterprise Mixture Settlement and investor presentation, might be offered in a Present Report on Type 8-Ok to be filed by Larkspur with the SEC which will be accessed at www.sec.gov in addition to on-line at www.lsprhealth.com.

Individuals within the Solicitation

Larkspur, ZyVersa, and their respective administrators and govt officers could also be deemed to be individuals within the solicitation of proxies from Larkspur’s stockholders in reference to the proposed Transaction. Details about Larkspur’s administrators and govt officers and their possession of Larkspur’s securities is ready forth in Larkspur’s Annual Report for the 12 months ended December 31, 2021, which was filed with the SEC on Type 10-Ok, as modified or supplemented by any Type 3 or Type 4 filed with the SEC because the date of such submitting. Different data relating to the pursuits of the individuals within the proxy solicitation might be included within the proxy assertion/prospectus pertaining to the proposed Transactions when it turns into obtainable. These paperwork will be obtained freed from cost from the sources indicated above.

No Supply or Solicitation

This communication doesn’t represent a proposal to promote or the solicitation of a proposal to purchase any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction through which such supply, solicitation, or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of such different jurisdiction.

Ahead Trying Statements

This press launch incorporates sure forward-looking statements throughout the which means of the federal securities legal guidelines with respect to the proposed transaction between Larkspur Well being Acquisition Corp. (“Larkspur”), and ZyVersa Therapeutics, Inc. (“ZyVersa”). All statements apart from statements of historic information contained on this press launch, together with statements relating to Larkspur or ZyVersa’s future outcomes of operations and monetary place, the amount of money anticipated to be obtainable to ZyVersa after the closing and giving impact to any redemptions by Larkspur’s stockholders, ZyVersa’s enterprise technique, potential product candidates, product approvals, analysis and growth prices, timing and probability of success, plans and targets of administration for future operations, future outcomes of present and anticipated product candidates, and anticipated use of proceeds, are forward-looking statements. These forward-looking statements usually are recognized by the phrases “consider,” “venture,” “count on,” “anticipate,” “estimate,” “intend,” “technique,” “future,” “alternative,” “plan,” “could,” “ought to,” “will,” “would,” “might be,” “will proceed,” “will seemingly consequence,” and related expressions. These forward-looking statements are topic to a variety of dangers, uncertainties and assumptions, together with, however not restricted to, the next dangers regarding the proposed transaction: the incidence of any occasion, change or different circumstances that would give rise to the termination of the Enterprise Mixture Settlement; the chance that the transaction will not be accomplished in a well timed method or in any respect, which can adversely have an effect on the worth of Larkspur’s securities; the incidence of any occasion, change or different circumstances that would give rise to the termination of the Enterprise Mixture Settlement; the shortcoming to finish the Transactions, together with on account of failure to acquire approval of the shareholders of Larkspur or different circumstances to closing within the Enterprise Mixture Settlement; the shortcoming to acquire or preserve the itemizing of Larkspur’s frequent inventory on NASDAQ following the Transactions; the chance that the Transactions disrupt present plans and operations of ZyVersa because of the announcement and consummation of the Transactions; the flexibility to acknowledge the anticipated advantages of the Transactions, which can be affected by, amongst different issues, competitors, the flexibility of the mixed firm to develop and handle development economically and rent and retain key staff; the dangers that ZyVersa’s product candidates in growth fail scientific trials or usually are not accredited by the U.S. Meals and Drug Administration or different relevant authorities; prices associated to the Transactions; adjustments in relevant legal guidelines or laws; the chance that Larkspur or ZyVersa could also be adversely affected by different financial, enterprise, and/or aggressive components; and different dangers and uncertainties to be recognized within the proxy assertion/prospectus (when obtainable) regarding the Transactions, together with these underneath “Threat Elements” therein, and in different filings with the SEC made by Larkspur. Furthermore, ZyVersa operates in a really aggressive and quickly altering setting. As a result of forward-looking statements are inherently topic to dangers and uncertainties, a few of which can’t be predicted or quantified and a few of that are past Larkspur’s and ZyVersa’s management, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and besides as required by regulation. Larkspur and ZyVersa assume no obligation and don’t intend to replace or revise these forward-looking statements, whether or not because of new data, future occasions, or in any other case. Neither Larkspur nor ZyVersa provides any assurance that both Larkspur or ZyVersa or the mixed firm will obtain its expectations.

SOURCE ZyVersa Therapeutics, Inc.; Larkspur Well being Acquisition Corp.